152 related articles for article (PubMed ID: 36636635)
1. Efficacy of Secukinumab in Psoriasis: Post Hoc Gender-Wise Analysis of the SUPREME Study.
Stingeni L; Malara G; Conti A; Di Costanzo L; Carrera CG; Burlando M; Malagoli P; Musumeci ML; Bardazzi F; Brazzelli V; Amerio P; De Simone C; Trevisini S; Balato A; Megna M; Loconsole F; De Felice C; Bartezaghi M; Rausa A; Aloisi E; Orsenigo R; Costanzo A;
Clin Cosmet Investig Dermatol; 2023; 16():27-38. PubMed ID: 36636635
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study.
Talamonti M; Russo F; Malara G; Hansel K; Papini M; Cattaneo A; Parodi A; Chiricozzi A; Malagoli P; Bardazzi F; Brazzelli V; Dapavo P; Gisondi P; Zane C; Potenza C; Cantoresi F; Fargnoli MC; Trevisini S; Brianti P; Pescitelli L; Gigante G; Bartezaghi M; Caputo L; Aloisi E; Costanzo A;
Clin Cosmet Investig Dermatol; 2023; 16():847-852. PubMed ID: 37033782
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
Crowley JJ; Langley RG; Gordon KB; Pinter A; Ferris LK; Rubant S; Photowala H; Xue Z; Wu T; Zhan T; Beeck S; Shah M; Warren RB
Dermatol Ther (Heidelb); 2022 Feb; 12(2):561-575. PubMed ID: 35050485
[TBL] [Abstract][Full Text] [Related]
4. Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results).
Bagel J; Nia J; Hashim PW; Patekar M; de Vera A; Hugot S; Sheng K; Xia S; Gilloteau I; Muscianisi E; Blauvelt A; Lebwohl M
Dermatol Ther (Heidelb); 2018 Dec; 8(4):571-579. PubMed ID: 30334147
[TBL] [Abstract][Full Text] [Related]
5. Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study.
Talamonti M; Malara G; Natalini Y; Bardazzi F; Conti A; Chiricozzi A; Mugheddu C; Gisondi P; Piaserico S; Pagnanelli G; Amerio P; Potenza C; Cantoresi F; Fargnoli MC; Balato A; Loconsole F; Offidani A; Bonifati C; Prignano F; Bartezaghi M; Rausa A; Aloisi E; Orsenigo R; Costanzo A;
Acta Derm Venereol; 2021 Mar; 101(3):adv00422. PubMed ID: 33269404
[TBL] [Abstract][Full Text] [Related]
6. Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study.
van de Kerkhof PCM; Loewe R; Mrowietz U; Falques M; Pau-Charles I; Szepietowski JC
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):119-126. PubMed ID: 31465585
[TBL] [Abstract][Full Text] [Related]
7. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
Abrouk M; Nakamura M; Zhu TH; Farahnik B; Koo J; Bhutani T
J Dermatolog Treat; 2017 Sep; 28(6):488-491. PubMed ID: 28042711
[TBL] [Abstract][Full Text] [Related]
8. Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.
Thaçi D; Strober B; Gordon KB; Foley P; Gooderham M; Morita A; Papp KA; Puig L; Menter MA; Colombo MJ; Elbez Y; Kisa RM; Ye J; Napoli AA; Wei L; Banerjee S; Merola JF; Gottlieb AB
Dermatol Ther (Heidelb); 2022 Feb; 12(2):495-510. PubMed ID: 35025062
[TBL] [Abstract][Full Text] [Related]
9. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
Augustin M; Reich K; Yamauchi P; Pinter A; Bagel J; Dahale S; You R; Bruin G; Djimopoulos J; Paguet B; Charef P; Patekar M; Keefe D
Br J Dermatol; 2022 Jun; 186(6):942-954. PubMed ID: 34981829
[TBL] [Abstract][Full Text] [Related]
10. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
[TBL] [Abstract][Full Text] [Related]
11. Secukinumab treatment showed improved quality of life in patients with chronic plaque psoriasis in Australia: Results from the HOPE study.
Foley P; Spelman L; Murrell DF; Mate E; Tronnberg R; Lowe PM
Australas J Dermatol; 2022 Aug; 63(3):312-320. PubMed ID: 35816576
[TBL] [Abstract][Full Text] [Related]
12. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
Blauvelt A; Reich K; Tsai TF; Tyring S; Vanaclocha F; Kingo K; Ziv M; Pinter A; Vender R; Hugot S; You R; Milutinovic M; Thaçi D
J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
[TBL] [Abstract][Full Text] [Related]
13. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
Hampton P; Halliday A; Aassi M; Subramanian S; Jain M; Griffiths CEM
J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):928-937. PubMed ID: 33030755
[TBL] [Abstract][Full Text] [Related]
14. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study.
Reich K; Puig L; Szepietowski JC; Paul C; Lacour JP; Tsianakas A; Sieder C; Rissler M; Pournara E; Orsenigo R
Br J Dermatol; 2020 Feb; 182(2):304-315. PubMed ID: 31102257
[TBL] [Abstract][Full Text] [Related]
15. Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis.
Gooderham M; Pinter A; Ferris LK; Warren RB; Zhan T; Zeng J; Soliman AM; Kaufmann C; Kaplan B; Photowala H; Strober B
J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):855-865. PubMed ID: 35174556
[TBL] [Abstract][Full Text] [Related]
16. Psoriatic patients treated with secukinumab reach high levels of minimal disease activity: results from the SUPREME study.
Campanati A; Diotallevi F; Radi G; Molinelli E; Brisigotti V; Martina E; Paolinelli M; Bianchelli T; Covi C; Bartezaghi M; Offidani A
Eur J Dermatol; 2021 Oct; 31(5):630-637. PubMed ID: 34789441
[TBL] [Abstract][Full Text] [Related]
17. Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab.
Elewski BE; Puig L; Mordin M; Gilloteau I; Sherif B; Fox T; Gnanasakthy A; Papavassilis C; Strober BE
J Dermatolog Treat; 2017 Sep; 28(6):492-499. PubMed ID: 28266243
[TBL] [Abstract][Full Text] [Related]
18. Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study.
Reich K; Körber A; Mrowietz U; Sticherling M; Sieder C; Früh J; Bachhuber T
Br J Dermatol; 2021 May; 184(5):849-856. PubMed ID: 32652528
[TBL] [Abstract][Full Text] [Related]
19. Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study.
Costanzo A; Russo F; Galluzzo M; Stingeni L; Scuderi R; Zichichi L; Papini M; Di Costanzo L; Conti A; Burlando M; Chiricozzi A; Gaiani FM; Mugheddu C; Musumeci ML; Gisondi P; Piaserico S; Dapavo P; Venturini M; Pagnanelli G; Amerio P; Potenza C; Peris K; Cantoresi F; Trevisini S; Loconsole F; Offidani A; Mercuri SR; Lora V; Prignano F; Bartezaghi M; Oliva G; Aloisi E; Orsenigo R
Acta Derm Venereol; 2021 Oct; 101(10):adv00576. PubMed ID: 33903916
[TBL] [Abstract][Full Text] [Related]
20. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Spuls PI; Hooft L
Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
